Overview
Zubsolv is approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid dependence. Zubsolv should be used as part of a complete treatment plan that includes counseling and psychosocial support. Healthcare providers may consider recommending or prescribing an opioid overdose reversal agent (e.g., naloxone) when starting or renewing Zubsolv treatment because individuals with opioid use disorder are at risk of relapse and overdose. Zubsolv is also known by its drug names, buprenorphine and naloxone. 

Zubsolv contains two drugs: buprenorphine and naloxone. Buprenorphine partially activates opioid receptors to reduce cravings and withdrawal symptoms. Naloxone blocks opioid effects if the medication is misused by injection, helping to prevent misuse.

How do I take it?
Prescribing information states that Zubsolv is administered sublingually (under the tongue) as a single daily dose after induction. Induction should be started when clear signs of opioid withdrawal are present to prevent sudden withdrawal symptoms. Initial doses are often given in divided amounts on the first day, with maintenance doses adjusted based on clinical response. Gradual tapering is recommended when discontinuing treatment to avoid withdrawal symptoms. Zubsolv should be taken exactly as directed by a healthcare provider. 

Side effects
Common side effects include headache, nausea, vomiting, hyperhidrosis (excessive sweating), constipation, withdrawal symptoms, insomnia, pain, and peripheral edema (swelling in the limbs).

Rare but serious side effects may include life-threatening respiratory depression, especially when combined with benzodiazepines or other central nervous system depressants; serotonin syndrome, a potentially fatal reaction caused by certain drug combinations; neonatal opioid withdrawal syndrome in newborns exposed to opioids during pregnancy; adrenal insufficiency (reduced hormone production); and risk of opioid withdrawal if treatment is abruptly stopped. Accidental exposure in children can cause severe respiratory depression or death.

For more information about this treatment, visit:
Label: Zubsolv — Buprenorphine Hydrochloride and Naloxone Hydrochloride Tablet, Orally Disintegrating — DailyMed